Eye drops containing an α1-blocker for inhibiting myopia progression
Patent Information
- Application Number
- MYPI2025001271
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-08-31
- Filing Date
- 2023-08-31
- Publication Date
- 2024-02-29
AI Technical Summary
Current treatments for suppressing myopia progression, particularly in school-age children and adults, are inadequate, as they often require medical intervention and may not effectively prevent axial elongation of the ocular axis, which is a primary cause of myopia and associated with various eye diseases.
Development of eye drops containing an α1 blocker, such as bunazosin, prazosin, urapidil, or moxisilt, at concentrations between 0.001 mg/mL and 1.4 mg/mL, which can be self-administered to suppress myopia progression by inhibiting axial elongation of the eye.
The eye drops effectively suppress myopia progression by reducing refractive power and axial length, as demonstrated in mouse models, with significant inhibition observed at concentrations above 0.01 mg/mL, allowing for a simple, non-invasive treatment option.
Smart Images

Figure PI2025001271_DRAWING_001 
Figure PI2025001271_DRAWING_002 
Figure PI2025001271_DRAWING_003
Abstract
Description
Eye drops containing an alpha-1 blocker to inhibit the progression of myopia
[0001] The present invention relates to an eye drop containing an α1 blocker for inhibiting the progression of myopia.
[0002] Myopia is particularly prevalent among Asians, especially Japanese, with a high proportion of severe myopia of -5D or greater. Myopia has been steadily increasing worldwide in recent years, and in Japan, the proportion of children with unaided visual acuity of less than 1.0 is increasing year by year. It is also known that myopia progresses rapidly during school age, between the ages of 7 and 12 (see Non-Patent Document 1).
[0003] Myopia is classified into refractive myopia, accommodative myopia (pseudomyopia), and axial myopia based on its onset mechanism. Myopia progression during school-age children is primarily axial myopia. Humans are hyperopic immediately after birth, but the degree of hyperopia decreases with axial elongation during growth, eventually becoming emmetropic as children enter school. This axial elongation after emmetropization directly leads to myopia, and once elongated, the axial length cannot be restored. Therefore, suppressing axial elongation during the growth and school-age period is considered effective for preventing or treating myopia (see Non-Patent Document 2). Furthermore, the axial elongation of the eye occurs not only during growth but also in adults, and axial elongation in adults is said to be a risk factor for various eye diseases.
[0004] Therapeutic agents for preventing myopia have been proposed, such as Rho kinase inhibitors (see Patent Document 1), bradykinin (Patent Document 2), and crocetin (Patent Document 3). The present inventor has also proposed an eye drop containing bunazosin for preventing myopia (Patent Document 4).
[0005] Medical Progress, Vol. 253, No. 2, 2015. Ophthalmology, Vol. 58, No. 6, 635-641, 2016.
[0006] WO2010 / 010702 JP 2011-144111 A WO2018 / 212152 Japanese Patent No. 6917103
[0007] An object of the present invention is to provide a novel eye drop for inhibiting the progression of myopia, which can inhibit the progression of myopia by a simple means.
[0008] The eye drops for inhibiting the progression of myopia according to the present invention are characterized by containing an α1 blocker. The α1 blocker is preferably contained in an amount of more than 0.001 mg / mL and not more than 1.4 mg / mL as an α1 blocker salt. The α1 blocker is preferably one or more selected from bunazosin, prazosin, urapidil, moxisilt, and corynanthine.
[0009] According to the present invention, myopic patients can suppress the progression of myopia by simply administering eye drops themselves, without the need for a doctor to give an injection at a medical institution.
[0010] These are photographs of mice used in myopia induction experiments (wearing a -30D lens in the right eye and a 0D lens in the left eye). (Experiment 1) These are the results of refraction when eye drops containing bunazosin, prazosin, and urapidil as alpha-1 blockers were instilled into myopic and non-myopic eyes. (Experiment 1) These are the results of axial length when eye drops containing bunazosin, prazosin, and urapidil as alpha-1 blockers were instilled into myopic and non-myopic eyes. (Experiment 2) These are the results of refraction when eye drops containing different amounts of alpha-1 blockers were instilled into myopic and non-myopic eyes. (Experiment 2) These are the results of axial length when eye drops containing different amounts of alpha-1 blockers were instilled into myopic and non-myopic eyes.
[0011] The present invention will be described below with reference to an α-blocker-containing eye drop for inhibiting the progression of myopia. The present invention is not limited to the following embodiments and examples, and includes various modifications and applications within the scope of the present invention.
[0012] The present invention provides an α1 blocker-containing eye drop solution that can suppress the progression of myopia by a simple method in which the myopic patient applies the solution to their eye, without the need for a doctor to directly inject the solution into their eye at a medical institution. In the present application, as in the experimental examples described below, a liquid eye drop solution containing an α1 blocker was applied to a mouse myopia model, and the refractive index and axial length were evaluated to verify the effect of suppressing the progression of myopia.
[0013] The eye drops are usually liquid eye drops (also called eye drops) provided in an eye dropper container. Such eye drops can be easily administered to the eyes by the myopic patient himself. Examples of α-1 blockers contained in the eye drops include bunazosin, prazosin, urapidil, moxisilt, and corinanthin, and the eye drops contain one or more of these.
[0014] The content of the α-1 blocker is preferably in the range of more than 0.001 mg / mL and not more than 1.4 mg / mL. As shown in Experiment 2 below, a concentration of 0.01 mg / mL or more is particularly preferred for the α-1 blocker salt. The dosage and administration method of the eye drops vary depending on the patient's symptoms, age, etc., but typically, about 1 to 2 drops are instilled about 1 to 6 times per day. While the upper limit of the content is not particularly limited, in the present application, a realistic upper limit concentration is set based on the solubility, etc., of the α-1 blocker salt used. For example, the solubility in water is 7.7 to 9.1 mg / mL for bunazosin hydrochloride, 1.4 mg / mL for prazosin hydrochloride, 25 mg / mL for urapidil hydrochloride, and about 5 mg / mL for doxazosin hydrochloride. Taking these factors into consideration, the upper limit of the α-1 blocker salt is set to 1.4 mg / mL.
[0015] Other ingredients that may be contained in the eye drops include pharmacologically active ingredients, physiologically active ingredients, glaucoma eye drop ingredients, etc., and these may be included within a range that does not impair the effects of the present invention. The eye drops may also optionally contain one or more other ingredients or additives, as needed, according to conventional methods, depending on the intended use and form, within a range that does not impair the effects of the present invention. Examples of such ingredients and additives include various additives such as fragrances or refreshing agents, preservatives, disinfectants or antibacterial agents, pH adjusters, chelating agents, stabilizers, isotonicity agents, and buffers. The inclusion of an α-1 blocker in a known eye drop can further enhance the effect of inhibiting the progression of myopia.
[0016] As described above, the present invention is an eye drop for inhibiting the progression of myopia containing an α1 blocker, but the present invention can also be expressed in other invention categories such as (i) use of a composition containing an α1 blocker as an eye drop for inhibiting the progression of myopia, (ii) use of a composition containing an α1 blocker for the manufacture of an eye drop for inhibiting the progression of myopia, (iii) a method for inhibiting the progression of myopia by instilling a composition containing an α1 blocker as an eye drop for progression inhibition, etc. Note that the "myopia progression inhibiting effect" referred to in this application refers to the effect of inhibiting the progression of axial myopia.
[0017] The following experiments further illustrate the invention.
[0018] [Measurement] As shown in Figure 1, 3-week-old mice (C57BL6 / J, CLEA Japan, Inc.) were fitted with a 0D lens ("D" stands for Diopter, a unit of lens refractive power) in the left eye and a -30D lens in the right eye, and myopia was induced for 3 weeks. During the myopia induction period, instillation of a drug into the eyes was administered once a day. PBS (Phosphate Buffered Saline) was administered as a control group, and α1 blocker instillation was administered as a test group. Bunazosin, prazosin, and urapidil were used as α1 blockers.
[0019] After 3 weeks, the refractive index and axial length of the mouse eyeball were measured, and the amount of change was calculated. Refraction values were measured using an infrared photoreflector for mice (made by Professor Schaeffel of the University of Tübingen). The more negative the refractive index, the more myopic the patient. Axial length was measured using spectral domain optical coherence tomography (Envisu R4310, manufactured by Leica). The larger the axial length value, the more myopic the patient.
[0020] [Experiment 1] (Experimental Method) PBS (control group), bunazosin eye drops (bunazosin hydrochloride 0.1 mg / mL), prazosin eye drops (prazosin hydrochloride 0.1 mg / mL), and urapidil eye drops (urapidil hydrochloride 0.1 mg / mL) were used as eye drops. The eye drops were administered once a day for three weeks during the myopia induction period.
[0021] (Experimental Results) Figure 2 shows the refractive index results. In the control group (PBS), eyes wearing -30D lenses became more myopic (-14.05 ± 3.71) than eyes wearing 0D lenses (2.55 ± 2.74). On the other hand, in the α1-blocker eye drop group, the difference between eyes wearing -30D lenses (-0.74 ± 4.07, -2.03 ± 5.33, -5.51 ± 6.29, respectively) and eyes wearing 0D lenses (3.65 ± 4.72, 3.97 ± 2.34, 0.33 ± 7.07, respectively) was small for all bunazosin, prazosin, and urapidil, and the progression of myopia was suppressed.
[0022] Figure 3 shows the results for axial length. In the control group (PBS), the axial length of eyes wearing -30D lenses (0.227 ± 0.015) was longer than that of eyes wearing 0D lenses (0.190 ± 0.014). Meanwhile, in the α1-blocker eye drops group, the difference in axial length between eyes wearing -30D lenses (0.191 ± 0.026, 0.200 ± 0.018, and 0.233 ± 0.020, respectively) and eyes wearing 0D lenses (0.187 ± 0.019, 0.190 ± 0.014, and 0.217 ± 0.014, respectively) was small for bunazosin, prazosin, and urapidil, indicating that myopia progression was suppressed.
[0023] From the above results, it was found that eye drops containing an α1 blocker have the effect of suppressing the progression of myopia.
[0024] [Experiment 2] (Experimental Method) The α-1 blocker eye drops were used with concentrations (mg of α-1 blocker salt contained in 1 mL: mg / mL) of 0.001 (mg / mL), 0.01 (mg / mL), and 0.1 (mg / mL). Each eye drop was administered once daily for three weeks during the myopia induction period. The control group received PBS eye drops containing no α-1 blocker, and the α-1 blocker eye drops contained bunazosin hydrochloride at a specified concentration.
[0025] (Experimental Results) Figure 4 shows the results of refractive index. In the PBS (control group) (α1 blocker concentration: 0 mg / mL), eyes wearing -30D lenses (-13.59 ± 3.35) became more myopic than eyes wearing 0D lenses (2.06 ± 2.02). Even in the group using eye drops with an α1 blocker concentration of 0.001 (mg / mL), eyes wearing -30D lenses (-10.90 ± 4.13) became more myopic than eyes wearing 0D lenses (-0.33 ± 3.47). The progression of myopia was slightly suppressed compared to the PBS (control group) (α1 blocker concentration: 0 mg / mL), and although a slight myopia progression suppression effect was observed, a sufficient myopia progression suppression effect was not obtained compared to when the α1 blocker concentration was 0.01 (mg / mL) or higher. Therefore, even if an α1 blocker concentration of 0.001 (mg / mL) is not sufficient, it was easy to infer that an α1 blocker concentration of more than 0.001 (mg / mL) would be effective in inhibiting the progression of myopia. On the other hand, in the groups in which α1 blocker concentrations of 0.01 (mg / mL) and 0.1 (mg / mL) were instilled, the difference between the eyes wearing -30D lenses (-6.92±4.08 and -1.26±3.28, respectively) and the eyes wearing 0D lenses (-0.83±3.20 and 3.19±3.76, respectively) was small, and the progression of myopia was inhibited.
[0026] Figure 5 shows the results for axial length. In the PBS (control group) (α1 blocker concentration: 0 mg / mL), eyes wearing -30D lenses had an elongated axial length (0.226 ± 0.017) compared to eyes wearing 0D lenses (0.194 ± 0.015). Even in the α1 blocker concentration 0.001 (mg / mL) eye drop group, eyes wearing -30D lenses had an elongated axial length (0.228 ± 0.017) compared to eyes wearing 0D lenses (0.196 ± 0.008). On the other hand, in the groups receiving eye drops containing an alpha-1 blocker at a concentration of 0.01 (mg / mL) and an alpha-1 blocker at a concentration of 0.1 (mg / mL), there was no difference in axial length between the eyes wearing -30D lenses (0.209±0.024 and 0.189±0.024, respectively) and the eyes wearing 0D lenses (0.192±0.021 and 0.180±0.028, respectively), and the progression of myopia was suppressed.
[0027] These results demonstrate that eye drops containing a specific concentration of alpha-1 blocker are effective in inhibiting the progression of myopia. It can be inferred that an alpha-1 blocker concentration of more than 0.001 mg / mL is effective in inhibiting the progression of myopia, and a sufficient effect in inhibiting the progression of myopia was confirmed, particularly when the alpha-1 blocker concentration was 0.01 mg / mL or higher.
Claims
1. An eye drop for inhibiting the progression of myopia, characterized by containing an alpha-1 blocker.
2. The eye drops for inhibiting the progression of myopia according to claim 1, wherein the alpha-1 blocker is contained in a range of more than 0.001 mg / mL and not more than 1.4 mg / mL as an alpha-1 blocker salt.
3. The eye drops for inhibiting the progression of myopia according to claim 1 or 2, wherein the alpha 1 blocker is one or more selected from bunazosin, prazosin, urapidil, moxisilt, and corynanthine.
4. Use of a composition containing an alpha-1 blocker as an eye drop for inhibiting the progression of myopia.
5. Use of a composition containing an alpha-1 blocker for the manufacture of eye drops for inhibiting the progression of myopia.
6. A method for inhibiting the progression of myopia by instilling a composition containing an alpha-1 blocker as an eye drop for inhibiting progression.
